ストックスクリーナーアプリを入手
4.31
4.86%
-0.22
Ernexa Therapeutics Inc (ERNA) 最新ニュース
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - Vinanet
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignCall Resistance - vinanet.vn
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics (ERNA) Poised at Support: Is the Consolidation Nearing an End?Virgin POC - dars.gov.et
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics Highlights ERNA-101 Combination-Therapy Potential, Preclinical Tumor Clearance Data and IND Progress - Quiver Quantitative
Ernexa's Innovative Approach to Cancer Treatment - Intellectia AI
Ernexa Therapeutics (ERNA) Plunges 10%: Key Support and Resistance Levels to WatchHidden Order - vinanet.vn
ERNA Q3 2023 Earnings: Loss Per Share Deepens, Stock Slides 16.39%Annual Earnings Summary - Vinanet
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.07: Minimal Price Action in Thin TradingRSI Overbought Alerts - vinanet.vn
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy - Sahm
3 Most Active Penny Stocks to Watch Today, 7/16/2026 - TipRanks
ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade
ERNA stock jumps as investors appear to refocus on ERNA-101 clinical milestones - Quiver Quantitative
ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance
ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap - timothysykes.com
Wednesday's pre-market session: top gainers and losers - ChartMill
Ernexa's ERNA-101 combo clears tumors and boosts survival in ovarian cancer preclinical study. - Pluang
Ernexa reports positive preclinical data for cancer therapy By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission - Quiver Quantitative
Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com - Investing.com Canada
Ernexa Therapeutics Receives Independent Validation of - GlobeNewswire
NeOnc, Ernexa, and VivoSim Announce Key Developments - Intellectia AI
Ernexa plans IND filing for ovarian cancer therapy ERNA-101 By Investing.com - Investing.com Canada
Ernexa Therapeutics plans first-in-human trial of ERNA-101 for ovarian cancer in late 2026 - Pluang
Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade - Stock Titan
Ernexa Therapeutics (ERNA) Rallies 3.3% as Biotech Sentiment ImprovesMESA MA - dars.gov.et
Ernexa Therapeutics Inc. Q3 2023 Earnings: Pre-Revenue Biotech Reports Net Loss Amid Pipeline ProgressAnalyst Drop Coverage - po-news-eg.net
Eterna Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosures - TipRanks
Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan - Stock Titan
ERNA Q3 2023 Earnings: Reported Loss per Share of -$1.03, Stock Rises $1.37Revenue Growth Outlook - dars.gov.et
ERNA stock shoots up 140% in a month: Here's what you should know - MSN
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):